Showing 20 of 40 recruiting trials for “Pleural mesothelioma”
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
👨⚕️ Kozo Kuribayashi, MD, PhD, Department of Respiratory Medicine and Hematology, Hyogo Medical University Hospital📍 1 site📅 Started Mar 2024View details ↗
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RecruitingNCT05628376 ↗
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
👨⚕️ Marjorie G Zauderer, MD, Memorial Slone Kettering (MSK) Cancer Centre📍 178 sites📅 Started Nov 2023View details ↗
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
👨⚕️ Gaetano Rocco, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Sep 2023View details ↗
RecruitingNCT05538806 ↗
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
RecruitingNCT06031636 ↗
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
RecruitingNCT06886672 ↗
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.
👨⚕️ Grigorios Stratakos, Professor, National and Kapodistrian University of Athens📍 1 site📅 Started May 2023View details ↗
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
👨⚕️ Zwi N Berneman, MD, PhD, Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine📍 3 sites📅 Started Feb 2023View details ↗
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
👨⚕️ Corey Langer, MD, University of Pennsylvania Abramson Cancer Center📍 1 site📅 Started Jan 2023View details ↗
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
The IMmunotherapy Pleural 5-ALA PDT
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Olaparib in Patients With HRD Malignant Mesothelioma
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
RecruitingNCT01851395 ↗
Rapid Autopsy and Procurement of Cancer Tissue
RecruitingNCT01950572 ↗
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
← PreviousPage 2 of 2
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →